CPT code 0447U designates a Proprietary Laboratory Analyses (PLA) test specific to the aiSLE® DX Flare Risk Index from Progentec Diagnostics Inc., which measures 11 plasma biomarkers by immunoassay and produces an algorithmic risk score for predicting systemic lupus erythematosus (SLE) flares. As a PLA code, 0447U is unique to a single manufacturer’s test and signals a growing portfolio of precision diagnostics that combine biomarker measurement with proprietary scoring algorithms. Nationally, PLA codes affect coverage policy development and utilization tracking because they identify discrete commercial assays rather than general test categories.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the test’s clinical purpose and service setting, payer coverage landscape at a high level, and the types of benchmarks and policy considerations typically relevant for PLA-coded diagnostics—such as coverage criteria, prior authorization trends, and reimbursement positioning. The publication also outlines clinical context for SLE flare risk assessment and what analysts and policy teams should monitor, including changes in payer medical policies, evidence requirements for clinical utility, and coding implications for laboratory billing. Data not available in the input is noted where applicable.